1. Overview
  2. All Stocks
  3. Aurora Cannabis Inc

Aurora Cannabis (ACB.US) Price Target 2026/2027: 115% Upside – Rating and Stock Analysis

2,91
0,00%
Analysis framework by , founder of TradeDesk · Data: EODHD, official filings (SEC) · Updated
Price history for Aurora Cannabis (ACB.US) – stock price at 2.91 $, August 2026
Aurora Cannabis stock price – price development 2026. Updated Aug 6, 2026.
Share this analysis:

Aurora Cannabis Price Target 2026: Analysts See 114% Upside

The average price target for Aurora Cannabis is $6.23. This price target represents the analysts' view of the stock price over the next 12 months. The stock may be undervalued, because the price target is higher than the current price. The stock is 114,09% below the target, which can point to potential returns within the next 12 months if the analysts' view proves right. Also consider the stock's valuation ratios such as P/E, P/S and P/B, plus the technical analysis further down the page, for the full picture.

Is Aurora Cannabis overvalued or undervalued?

Aurora Cannabis is currently undervalued with a gap of 114.1% relative to the price target.


The current price is $2.91, which places Aurora Cannabis in the undervalued category. The stock is considered undervalued when the price is below $5.61, and overvalued when the price exceeds $6.85.


The fair value range is defined as ±10% of the price target, because price targets are estimates rather than exact values. For Aurora Cannabis, the fair value range lies between $5.61 and $6.85.


See the full price target analysis for Aurora Cannabis →

↑ Back to navigation

Analyst Ratings for Aurora Cannabis stock in 2026: Buy

6 analysts cover Aurora Cannabis. The majority is positive, with 66.7% recommending Buy, while 33.3% recommend Hold. The average price target is $6.23, which gives an upside of 114.1% from the current price.

Consensus: Buy (4.17/5)
Strong Buy
3 (50%)
Buy
1 (16.7%)
Hold
2 (33.3%)
Strong Sell Sell Hold Buy Strong Buy
4.17 out of 5 based on 6 analysts
↑ Back to navigation

About Aurora Cannabis – Drug Manufacturers - Specialty & Generic

Aurora Cannabis laver og sælger cannabisprodukter i Canada og internationalt. De tjener primært penge på at dyrke, forske i og distribuere tørret cannabis, olier og kapsler til medicinske patienter. Virksomheden er kendt for deres egne stammer og de sælger også udstyr som vaporizere og kværne. Aurora Cannabis driver også CanvasRX, som er et netværk af rådgivningscentre for cannabisbrugere. De udvikler hele tiden nye medicinske produkter, for eksempel dem til oral, topisk eller inhalerbar brug. Aurora Cannabis blev grundlagt i 2006 og har siden udvidet deres aktiviteter til flere lande. Read more about the company

Key Figures for Aurora Cannabis

$ 174M Market cap
$ 321M Revenue
Drug Manufacturers - Specialty & Generic Industry
- P/E
0.54 P/S
0.47 P/B
USA Listed on exchange
auroramj.com Website
Sundhed Sector

What kind of stock is Aurora Cannabis?

Speculative stock

Aurora Cannabis is classified as a speculative stock.

Score Overview for Aurora Cannabis

💰 Value Score 58/100 (Neutral)
⭐ Quality Score 18/100 (Very Low)
🚀 Momentum Score 11/100 (Very Low)
📊 Total Score 29/100

⚠️ 5 red flags identified 4 critical

Our analysis has identified 5 potential risk factors in Aurora Cannabis that investors should be aware of.

🚨 Weak balance sheet (elevated risk): Altman Z2 is -25.63 – the balance sheet is measurably weaker than average. This is a risk signal based on the numbers, not a bankruptcy prediction.
🚨 Negative profit margin: The profit margin is -42.4% – the company is losing money on its operations.
⚠️ Negative return on equity: ROE is -10.5% – the company is generating a negative return for shareholders.
🚨 High short interest: 20.4% of the shares are sold short – many professional investors are betting on price declines.
🚨 Falling earnings: Quarterly earnings have fallen 95% year over year – the company's profitability is under pressure.

📈 Valuation

The P/S ratio is 0.5 (low — potentially undervalued relative to revenue). The P/B ratio is 0.5, below book value, which can point to a value opportunity.

💵 Profitability & Growth

The latest quarterly earnings grew -94.7% year over year — falling earnings.

🏦 Financial Health

The Piotroski score is 5 out of 9 — average financial health. Altman Z2 is -25.63 (weak balance sheet — elevated risk). The debt-to-equity ratio (D/E) is 43.0% — low debt, a solid balance sheet.

🚀 Momentum & Short Interest

Short interest is 20.42% — very high, the market is skeptical.

↑ Back to navigation

Aurora Cannabis Short Selling 2026: 20.4% Sold Short

Extremely shorted: 20.4% of the free float
Short % of free float
20.4%
Assessment
Extremely shorted
Short squeeze risk
Very High
Data source
SEC
Updated daily
The stock has an extremely high share of short selling. More than 20% of the freely traded shares are sold short, which is unusual and can point to great skepticism among institutional investors. The risk of a short squeeze on positive news is considerable.

What does this mean for you as an investor?
A short interest of 20.4% means that 20.4% of the freely traded shares in Aurora Cannabis have been borrowed and sold by investors betting on falling prices. On positive surprises (e.g. a strong earnings report), short sellers can be forced to buy back shares quickly to close their positions, which can cause a short squeeze with sharp price gains in a short time.

Data is updated daily based on official filings with the SEC.
Short Interest Scale
0% 2% 5% 10% 20%+
Low Moderate High Very High Extreme
▲
20.4%

↑ Back to navigation

When Does Aurora Cannabis Report Earnings?

The next earnings date for Aurora Cannabis is not yet available. Check the company's investor calendar for more information.



↑ Back to navigation

Technical Analysis of Aurora Cannabis 2026 – Signal: Strong Sell

Overall Technical Signal: Strong Sell

Based on trend analysis (SMA50/SMA200) and MACD trend (positive/negative on a daily + weekly basis). Updated August 6, 2026.

Technical analysis of Aurora Cannabis (ACB.US) – RSI 59, MACD negative (bearish), daily candlestick chart August 2026
Aurora Cannabis technical analysis – candlestick chart with RSI and MACD. Updated Aug 6, 2026.

Trend Analysis of Aurora Cannabis Inc

Aurora Cannabis Inc is in a short-term uptrend. The price of $2.91 is 7.3% above the 20-day average ($2.71). Medium term, the picture is negative: the price is 1.3% below the 50-day average ($2.95). Long term, the stock is 22.4% below the 200-day average ($3.75), which signals a long-term downtrend.

Death Cross: The 50-day average (2.95) is below the 200-day average (3.75), which is a classic bearish signal for Aurora Cannabis Inc.

Is Aurora Cannabis Inc overbought or oversold?

Aurora Cannabis Inc has an RSI of 59.0. The stock shows positive momentum in the upper part of the neutral zone.

MACD Analysis for Aurora Cannabis Inc

Daily MACD: MACD is negative (-0.014), which means the short-term trend is bearish (the 12-day EMA is below the 26-day EMA). MACD is above the signal line (-0.056) by 0.042, which suggests the negative momentum is fading – a potential trend reversal could be ahead.

Weekly MACD: MACD5 is negative (-0.361), which indicates a broader bearish long-term trend. MACD5 is below the signal line (-0.346) by 0.015, which confirms continued negative long-term momentum.

Overall MACD assessment: Both the daily and weekly trend are bearish (MACD negative). However, momentum shows signs of improving on a daily basis – a potential trend reversal could be ahead, but it is not confirmed yet.

Risk Profile for Aurora Cannabis Inc

Aurora Cannabis Inc has an annual standard deviation of 63.2%, which classifies the stock as high risk. Sizeable price swings are normal, and the stock requires a higher risk tolerance.

Overall Technical Conclusion for Aurora Cannabis Inc

Trend: Negative. The price trades below SMA50 and SMA200.

MACD trend (zero line): Daily bearish (-0.014). Weekly bearish (-0.361).

MACD momentum (signal): Daily rising. Weekly falling.

RSI: 59.0 – neutral.

Technical signal: Strong Sell

The price is in a downtrend (below SMA50/SMA200) and MACD is negative on both a daily and weekly basis. Avoid buying and consider closing existing positions.

↑ Back to navigation

Frequently Asked Questions About Aurora Cannabis stock in 2026

Should you buy Aurora Cannabis stock now?
No, the technical signal for Aurora Cannabis is currently SELL. Aurora Cannabis trades at $2.91 as of 8/6/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.014 with rising momentum (signal: -0.056); RSI is at 59.0 (neutral zone); the stock is in a short-term uptrend (price above the 20-day average); the analyst price target of $6.23 points to 114.1% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Aurora Cannabis stock?
The average analyst price target for Aurora Cannabis is $6.23. The current price is $2.91, which gives an upside of 114.1%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $5.61 and $6.85.
Is Aurora Cannabis a dividend stock?
No, Aurora Cannabis does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Aurora Cannabis stock?
Aurora Cannabis is rated as a stock with high risk. the annual standard deviation is 63.2%, which classifies the stock as high risk.
Is Aurora Cannabis overvalued?
No, Aurora Cannabis is considered undervalued based on the analyst price target (114.1% upside). Aurora Cannabis has the following valuation ratios: a P/S ratio of 0.5, a P/B ratio of 0.5. The analyst price target suggests that the stock is undervalued by 114.1%.
Is Aurora Cannabis overbought?
No, Aurora Cannabis is not overbought. RSI is at 59.0 (neutral zone). The technical indicators show: RSI is at 59.0 (neutral zone between 30-70), which signals neither overbought nor oversold. In addition, the price is 7.3% above the 20-day average (short-term uptrend). In addition, MACD is negative, but momentum is rising (possible trend reversal).
When is the next Aurora Cannabis earnings report?
The date of the next earnings report for Aurora Cannabis has not been published yet. Check the company's investor calendar for updates.
Is Aurora Cannabis shorted?
Yes, Aurora Cannabis is shorted with 20.4% of the free float sold short. This is an extremely high level of short selling, which points to great skepticism among institutional investors. The risk of a short squeeze on positive news or earnings is very high. Data is updated daily based on official filings with the SEC.
Are insiders buying Aurora Cannabis stock?
There is currently no registered insider trading for Aurora Cannabis.
Is Aurora Cannabis a good stock?
Based on our total score, Aurora Cannabis is rated as a poor stock with a total score of 29 out of 100. The stock scores below average on value, quality and momentum – it sits at the lower end of the market. The score is made up of Value: 58/100, Quality: 18/100, Momentum: 11/100. In addition: analysts see 114.1% upside to the price target; technical signal: Strong Sell. Whether Aurora Cannabis is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Aurora Cannabis stock?
The outlook for Aurora Cannabis based on current data: the average analyst price target is $6.23 (+114.1%); the stock is in a downtrend (below SMA50 and SMA200). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Aurora Cannabis stock rising?
Aurora Cannabis is rising right now. The technical indicators show: the price is 7.3% above the 20-day average; short interest is 20.4% (high – many are betting on a decline). For the latest context, see our technical analysis, insider section and news overview above.
How high can Aurora Cannabis go?
The average analyst price target for Aurora Cannabis is $6.23, which corresponds to a potential gain of 114.1% from the current price of $2.91. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Aurora Cannabis fall?
We lack enough history to give a specific floor for Aurora Cannabis. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Aurora Cannabis do?
Aurora Cannabis laver og sælger cannabisprodukter i Canada og internationalt. De tjener primært penge på at dyrke, forske i og distribuere tørret cannabis, olier og kapsler til medicinske patienter. Virksomheden er kendt for deres egne stammer og de sælger også udstyr som vap... The company belongs to the Sundhed sector, more specifically the Drug Manufacturers - Specialty & Generic industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Aurora Cannabis as an investment.
Did Aurora Cannabis raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Aurora Cannabis. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Aurora Cannabis making money or losing money?
No, Aurora Cannabis is currently not making money — the company is losing money with a negative profit margin of -42.4%, a substantial loss. That means the business loses money on every dollar of revenue. For growth stocks investing in expansion this is normal — but it raises the risk if the company does not reach break-even before its capital runs out.
Can Aurora Cannabis go bankrupt?
The bankruptcy risk of Aurora Cannabis is rated as elevated. Altman Z2 (a model for assessing financial distress) is -25.63 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 5 — which is average. Debt relative to equity is 43% (low). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Aurora Cannabis have a lot of debt?
No, Aurora Cannabis has low debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 43%. For the sundhed sector, anything below 80% counts as low debt. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
↑ Back to navigation

Explore More